Novel BTK Inhibitors: Effects on Adaptive and Innate Immunity in Multiple Sclerosis


Program Dates: July 1, 2020 - June 30, 2021
Credits: 1.50 AMA PRA Category 1 Credits™; 1.50 CNE Contact Hours; 1.50 CPE Contact Hours


Novel BTK Inhibitors: Effects on Adaptive and Innate Immunity in Multiple Sclerosis

Program Overview

This CME/CE program will highlight novel BTK (Bruton’s tyrosine kinase) inhibitors and their effects on adaptive and innate immunity in multiple sclerosis (MS). The expert faculty, led by Dr. Fred D. Lublin, will review BTK inhibitor science as a therapeutic target to reduce neuroinflammation and damage to the CNS in patients with MS. The faculty will analyze the safety and efficacy of ongoing BTK inhibitor clinical trials to improve the management of patients with relapsing and progressive forms of multiple sclerosis. Treatment strategies for the application of newer disease-modifying therapeutics to optimize outcomes in patients with MS will be discussed. Upon completion of this activity, clinicians will gain further insight into novel BTK inhibitors and their effect on patients with multiple sclerosis.

Target Audience

Neurologists, nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals involved in the management of patients with multiple sclerosis

Agenda

I. Why We Need New Approaches to Treating MS – Fred D. Lublin, MD
II. The Science of BTK Inhibitors: Adaptive and Innate Immunity – Benjamin M. Greenberg, MD, MHS
III. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel BTK Inhibitors – Mark S. Freedman, MD
IV. Faculty Panel Discussion: Treatment Strategies for the Application of BTK-Inhibitor Therapeutics to Optimize MS Patient Outcomes & Audience Q&A – Fred D. Lublin, MD & Faculty

Learning Objectives

  1. Understand BTK inhibitor science as a therapeutic target to reduce neuroinflammation and damage to the CNS in patients with MS.
  2. Analyze ongoing clinical trials for the efficacy and safety of novel BTK inhibitors to improve the management of patients with relapsing and progressive forms of MS.
  3. Discuss treatment strategies for the application of newer disease-modifying therapeutics to optimize outcomes in patients with MS.

Faculty

Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York

 

Mark S. Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

 

Benjamin M. Greenberg, MD, MHS
Vice Chair of Translational Research
Department of Neurology and Neurotherapeutics
Director, Neuroimmunology Programs
UT Southwestern Medical Center
Children’s Medical Center
Dallas, Texas

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Fred D. Lublin, MD Consultant/Advisor: Acorda Therapeutics, Inc.; Actelion Pharmaceuticals Ltd./Janssen Pharmaceutica; Apitope; Atara Biotherapeutics; Avotres Inc.; Biogen, Inc.; Brainstorm Cell Therapeutics; EMD Serono, Inc.;  GW Pharma; Immunic Therapeutics; Innate Immunotherapeutics; Jazz Pharmaceuticals; Mapi Pharma; MedDay Pharma; MedImmune LLC/Viela Bio; Mylan Pharmaceuticals; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma Biologics; Population Council; Receptos Inc./Celgene Corporation; Roche Pharma/Genentech Inc.; Sanofi/Genzyme; Teva Pharmaceuticals; TG Therapeutics

Grant/Research Support:  Actelion Pharamaceuticals Ltd.; Biogen, Inc.; Brainstorm Cell Therapeutics; Novartis Pharmaceuticals Corporation; Sanofi

Speaker’s Bureau: Sanofi Genzyme

Mark S. Freedman, MD

 

Consultant/Advisor: Actelion Pharmaceuticals, Ltd. (Janssen Pharmaceutica); Alexion Phramaceuticals, Inc.; Atara Biotherapeutics; Bayer Healthcare Pharmaceuticals LLC; Biogen, Inc.; Celgene Corporation (Bristol Myers Squibb); Clene Nanomedicine, Inc.; GRI Bio, Inc.; Hoffman La-Roche AG; Magenta Therapeutics; Merck Serono; MedDay Pharma; Novartis Pharmaceuticals Corporation; Sanofi Genzyme; Teva Pharmaceuticals Canada Innovation

Grant/Research Support: EMD Inc. (Canada); Hoffman-La Roche AG; Sanofi Genzyme Canada

Speaker’s Bureau: EMD Serono; Sanofi-Genzyme

Receipt of honoraria or consultation fees: Actelion Pharmaceuticals, Ltd. (Janssen Pharamaceutica); Alexion Pharmaceuticals, Inc.; Biogen, Inc; Celgene Corporation (Bristol Meyers Squibb); EMD Inc.; Sanofi Genzyme; Hoffman La-Roche AG; Merck Serono; Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals Canada Innovation

Benjamin M. Greenberg, MD, MHS

 

Consultant/Advisor: Abcam; Alexion Pharmaceuticals; Axon Advisors LLC; EMD Serono, Inc.; Greenwich Biosciences, Inc.; Hoffman La-Roche AG; Novartis Pharmaceuticals Corporation; Rubin/Anders; Viela Bio.

Grant/Research Support: Clene Nanomedicine; Guthy Jackson Charitable Foundation; NIH; NMSS; PCORI; TMA

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.5 AMA PRA Category 1 CreditsTM.

AcademicCME designates this live material for a maximum of 1.5 CNE Contact Hours, including 1.5 pharmacotherapeutic contact hour (Provider number P0491).

AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15s CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-20-006-H04-P).

Financial Support

This activity has been supported by an independent educational grant from Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web